Sort   by:  
 Page size 
ProteomicsIdentification of regulators of polyploidization presents therapeutic targetsfor treatment of AMKL
Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, Wang LZ, Lewis TA, An WF, Li X, Bray MA, Thiollier C, Diebold L, Gilles L, Vokes MS, Moore CB, Bliss-Moreau M, Verplank L, Tolliday NJ, Mishra R, Vemula S, Shi J, Wei L, Kapur R, Lopez CK, Gerby B, Ballerini P, Pflumio F, Gilliland DG, Go...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2014-01-27 | MSV000078536 | MassIVE
GenomicsBET Bromodomains Mediate Transcriptional Pause Release in Heart Failure [ChIP-Seq]
Heart failure is driven by the interplay between master regulatory transcription factors and dynamic alterations in chromatin structure. Coordinate activation of developmental, inflammatory, fibrotic and growth regulators underlies the hallmark phenotypes of pathologic cardiac hypertrophy and contra...
ORGANISM(S): Mus musculus 
2013-08-06 | E-GEOD-46668 | biostudies-arrayexpress
TranscriptomicsPrimary human erythroid progenitor cells HDAC1 and HDAC2 shRNA knockdown samples
Gene expression profiling was performed on primary human erythroid progenitor cells expressing a control shRNA (luciferase), two different HDAC1 shRNAs, and two different HDAC2 shRNAs. The worldwide burden of sickle cell disease is enormous, with over 200,000 infants born with the disease each year ...
ORGANISM(S): Homo sapiens 
2010-07-29 | E-GEOD-22366 | biostudies-arrayexpress
GenomicsDiscovery and Characterization of Super-Enhancer Associated Dependencies in Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL) is a biologically heterogeneous and clinically aggressive disease. Here, we explore the role of BET bromodomain proteins in DLBCL, using integrative chemical genetics and functional epigenomics. We observe highly asymmetric loading of BRD4 at enhancers, with app...
ORGANISM(S): Homo sapiens 
2013-12-10 | E-GEOD-46663 | biostudies-arrayexpress
TranscriptomicsPrimary human erythroid progenitor cells SAHA treatment samples
Gene expression profiling was performed on primary human erythroid progenitor cells left untreated or treated with 0.5uM SAHA. The worldwide burden of sickle cell disease is enormous, with over 200,000 infants born with the disease each year in Africa alone. Induction of fetal hemoglobin is a valida...
ORGANISM(S): Homo sapiens 
2010-07-29 | E-GEOD-22367 | biostudies-arrayexpress
TranscriptomicsHDAC6 and HSP90 control the functions of Foxp3+ T regulatory cells
Foxp3+ T-regulatory cells (Tregs) are key to immune homeostasis such that their diminished numbers or function can cause autoimmunity and allograft rejection. Foxp3+ Tregs express histone/protein deacetylases (HDACs) that regulate chromatin remodeling, gene expression and protein function. Pan-HDAC ...
ORGANISM(S): Mus musculus 
2011-05-01 | E-GEOD-27896 | biostudies-arrayexpress
UnknownMechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.
Not available
S-EPMC5388135 | biostudies-literature
TranscriptomicsResponse and resistance to BET bromodomain inhibitors in triple negative breast cancer [RNA-Seq]
Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. Here we report the preferential and high sensitivity of TNBCs to BET bromodomain inhibitors such as JQ1 manifested by cell cycle arrest in early G1, apoptosis, and induct...
ORGANISM(S): Homo sapiens 
2016-01-07 | E-GEOD-63582 | biostudies-arrayexpress
GenomicsResponse and resistance to BET bromodomain inhibitors in triple negative breast cancer [ChIP-Seq]
Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. Here we report the preferential and high sensitivity of TNBCs to BET bromodomain inhibitors such as JQ1 manifested by cell cycle arrest in early G1, apoptosis, and induct...
ORGANISM(S): Homo sapiens 
2016-01-07 | E-GEOD-63581 | biostudies-arrayexpress
GenomicsResponse and resistance to BET bromodomain inhibitors in triple negative breast cancer [Chem-Seq]
Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. Here we report the preferential and high sensitivity of TNBCs to BET bromodomain inhibitors such as JQ1 manifested by cell cycle arrest in early G1, apoptosis, and induct...
ORGANISM(S): Homo sapiens 
2016-01-07 | E-GEOD-63284 | biostudies-arrayexpress
Sort   by:  
 Page size